A novel data science and network analysis approach to quantifying facilitators and barriers of low tidal volume ventilation in an international consortium of medical centers
一种新颖的数据科学和网络分析方法,用于量化国际医疗中心联盟中低潮气量通气的促进因素和障碍
基本信息
- 批准号:10430058
- 负责人:
- 金额:$ 68.09万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-09 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAcute Respiratory Distress SyndromeAdmission activityAdoptionAffectAttitudeCaringCharacteristicsCohort StudiesCommunity HospitalsComplexConsolidated Framework for Implementation ResearchCritical IllnessDataData ScienceDiffusion of InnovationEnvironmentEvidence based practiceGoalsHealthHealthcare SystemsHeightHigh PrevalenceHypoxemiaIndividualInflammatoryIntensive Care UnitsInternationalInterventionInvestigationKnowledgeLeadMachine LearningMeasurementMedical centerMethodsModelingNational Heart, Lung, and Blood InstituteNursesPathway AnalysisPatient-Focused OutcomesPatientsPerformancePhysiciansProfessional OrganizationsPulmonary EdemaResearchSeveritiesSpeedStructureSurveysSyndromeSystemTestingTidal VolumeVariantbasecommunity settingcomplex datacomputer sciencedissemination researcheffective therapyexperimental studyhealth care settingsimplementation researchimplementation scienceimplementation strategylung injurymachine learning methodmortalitymultidisciplinarynovelrespiratoryresponsetheoriesventilation
项目摘要
PROJECT SUMMARY/ABSTRACT
This application, “A novel data science and network analysis approach to quantifying facilitators and
barriers of low tidal volume ventilation in an international consortium of medical centers,” is in response to
PAR-16-238, Dissemination and Implementation Research in Health (R01). Acute respiratory distress
syndrome (ARDS) has high prevalence (10% of intensive care unit admissions) and mortality up to 46%. Low
tidal volume ventilation (LTVV) is the most effective therapy for ARDS, lowering mortality by 20-25%, and is
part of standard practice. However, use of LTVV is as low as 19% of ARDS patients. There is a poor
understanding of the barriers to LTVV adoption: current approaches are deficient because they incorporate
biases, lack consistency and comprehensiveness, ignore the influence of interpersonal network- or team-
based factors, and do not address setting-specific variation. Our research team has previously identified some
patient- and clinician-specific facilitators of and barriers to LTVV adoption. We have used two state-of-the-art
data driven methods—data science and network analysis—to preliminarily quantify the impact of a diverse
array of potential factors affecting LTVV adoption, including network- and team-based factors. The proposed
research is guided by the Consolidated Framework for Implementation Research (CFIR) and Rogers' Diffusion
of Innovations theory. The overall goals of the proposed research are to understand the differences in
facilitators and barriers to LTVV adoption between academic and community settings through a definitive,
systematic study in a large, diverse consortium of medical centers, and to advance implementation science by
providing a model for how data science and network analysis can be applied to understand the adoption of a
complex intervention. The overarching hypothesis is that there are different patient-, clinician-, network-, and
team-based facilitators and barriers to LTVV adoption in academic and community settings. We will determine
whether different patient- and clinician- (Aim 1 cohort study, clinician survey, and data science analysis),
clinician interpersonal network- (Aim 2 network analysis), and team structure and dynamics-based (Aim 3 team
construction and modeling) facilitators of and barriers to LTVV adoption exist between academic and
community hospital settings. Successful completion of the proposed research will provide a comprehensive
understanding of the differences in the facilitators of and barriers to LTVV adoption between academic and
community settings, and will advance implementation science by serving as a model of how data science and
network analysis can be applied to complex implementation problems. Implementation strategies that account
for all these factors may be more likely to lead to significant practice change.
项目总结/摘要
这个应用程序,“一种新颖的数据科学和网络分析方法来量化促进者和
国际医学中心联盟中低潮气量通气的障碍,”是对
PAR-16-238,《健康领域的传播和实施研究》(R 01)。急性呼吸窘迫
急性呼吸窘迫综合征(ARDS)的患病率很高(占重症监护病房入院人数的10%),死亡率高达46%。低
潮气量通气(LTVV)是治疗ARDS最有效的方法,可使死亡率降低20- 25%,
标准做法的一部分。然而,LTVV的使用率低至19%的ARDS患者。有一所穷人
理解LTVV采用的障碍:目前的方法是有缺陷的,因为它们包含
偏见,缺乏一致性和全面性,忽视人际网络或团队的影响,
基于因素,不解决设置特定的变化。我们的研究团队之前已经发现了一些
采用LTVV的患者和临床医生特定促进因素和障碍。我们用了两个最先进的
数据驱动的方法-数据科学和网络分析-初步量化的影响,
影响LTVV采用的一系列潜在因素,包括基于网络和团队的因素。拟议
研究工作以实施研究的统一框架(CFIR)和罗杰斯的扩散理论为指导
创新理论。拟议研究的总体目标是了解
促进者和障碍,LTVV通过学术和社区环境之间的一个明确的,
在一个大型的、多样化的医疗中心联盟中进行系统研究,并通过以下方式推进实施科学:
提供了一个模型,说明如何应用数据科学和网络分析来理解
复杂的干预。总体假设是,存在不同的患者、临床医生、网络和
在学术和社区环境中采用LTVV的团队促进者和障碍。我们将确定
无论患者和临床医生是否不同(Aim 1队列研究、临床医生调查和数据科学分析),
临床医生人际网络-(目标2网络分析),团队结构和动态为基础的(目标3团队
构建和建模)学术界和学术界之间存在LTVV采用的促进因素和障碍
社区医院设置。成功完成拟议的研究将提供全面的
理解学术和学术之间采用LTVV的促进因素和障碍的差异
社区环境,并将通过作为数据科学和
网络分析可以应用于复杂的实现问题。实施战略,
因为所有这些因素可能更有可能导致重大的做法改变。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Promoting Evidence-Based Practice in Acute Respiratory Distress Syndrome: A Systematic Review.
- DOI:10.1097/cce.0000000000000391
- 发表时间:2021-04
- 期刊:
- 影响因子:0
- 作者:Giovanni SP;Jennerich AL;Steel TL;Lokhandwala S;Alhazzani W;Weiss CH;Hough CL
- 通讯作者:Hough CL
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Curtis H. Weiss其他文献
Curtis H. Weiss的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Curtis H. Weiss', 18)}}的其他基金
A novel data science and network analysis approach to quantifying facilitators and barriers of low tidal volume ventilation in an international consortium of medical centers
一种新颖的数据科学和网络分析方法,用于量化国际医疗中心联盟中低潮气量通气的促进因素和障碍
- 批准号:
10178076 - 财政年份:2018
- 资助金额:
$ 68.09万 - 项目类别:
A novel implementation and social network strategy for acute pulmonary illnesses
急性肺部疾病的新型实施和社交网络策略
- 批准号:
8882543 - 财政年份:2013
- 资助金额:
$ 68.09万 - 项目类别:
A novel implementation and social network strategy for acute pulmonary illnesses
急性肺部疾病的新型实施和社交网络策略
- 批准号:
8487124 - 财政年份:2013
- 资助金额:
$ 68.09万 - 项目类别:
A novel implementation and social network strategy for acute pulmonary illnesses
急性肺部疾病的新型实施和社交网络策略
- 批准号:
8714043 - 财政年份:2013
- 资助金额:
$ 68.09万 - 项目类别:
相似海外基金
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 68.09万 - 项目类别:
Research Grant
The Association Between Aging, Inflammation, and Clinical Outcomes in Acute Respiratory Distress Syndrome
衰老、炎症与急性呼吸窘迫综合征临床结果之间的关联
- 批准号:
10722669 - 财政年份:2023
- 资助金额:
$ 68.09万 - 项目类别:
Sedatives Pharmacology in Acute Respiratory Distress Syndrome- SPA
急性呼吸窘迫综合征中的镇静药理学 - SPA
- 批准号:
491387 - 财政年份:2023
- 资助金额:
$ 68.09万 - 项目类别:
Fellowship Programs
New mechanism-based TREM-1 therapy for acute respiratory distress syndrome
基于新机制的 TREM-1 疗法治疗急性呼吸窘迫综合征
- 批准号:
10678788 - 财政年份:2023
- 资助金额:
$ 68.09万 - 项目类别:
Great Lakes Clinical Center of the Acute Respiratory Distress Syndrome, Pneumonia and Sepsis (APS) Consortium
急性呼吸窘迫综合征、肺炎和败血症 (APS) 联盟五大湖临床中心
- 批准号:
10646578 - 财政年份:2023
- 资助金额:
$ 68.09万 - 项目类别:
Effect of ADAMTS13 on pathogenesis of acute respiratory distress syndrome
ADAMTS13 对急性呼吸窘迫综合征发病机制的影响
- 批准号:
23K08447 - 财政年份:2023
- 资助金额:
$ 68.09万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)
一种新型合成生物学衍生的微生物疗法,可治疗病毒引起的急性呼吸窘迫综合征(ARDS)
- 批准号:
10601865 - 财政年份:2023
- 资助金额:
$ 68.09万 - 项目类别:
Development of drug therapy targeting ferroptosis, iron-dependent cell death for acute respiratory distress syndrome.
开发针对铁死亡(急性呼吸窘迫综合征的铁依赖性细胞死亡)的药物疗法。
- 批准号:
23K08360 - 财政年份:2023
- 资助金额:
$ 68.09万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Sustainable Implementation of Prone Positioning for the Acute Respiratory Distress Syndrome
持续实施俯卧位治疗急性呼吸窘迫综合征
- 批准号:
10722194 - 财政年份:2023
- 资助金额:
$ 68.09万 - 项目类别:
Point-of-care system to assess the risk of trauma-induced acute respiratory distress syndrome
用于评估创伤引起的急性呼吸窘迫综合征风险的护理点系统
- 批准号:
10594793 - 财政年份:2023
- 资助金额:
$ 68.09万 - 项目类别: